Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Cybin ( (TSE:CYBN) ).
Cybin has launched strategic clinical site partnerships to accelerate its PARADIGM program, a multinational Phase 3 initiative evaluating CYB003 for treating major depressive disorder. This program includes multiple studies across over 40 sites in the U.S. and Europe, with a significant addressable market of over 300 million people. With a robust drug development team and Breakthrough Therapy Designation from the FDA, Cybin aims to shift depression treatment towards more intermittent therapies rather than daily dosing.
More about Cybin
Cybin Inc. is a clinical-stage breakthrough neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options.
YTD Price Performance: -4.36%
Average Trading Volume: 388,606
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.37M
See more data about CYBN stock on TipRanks’ Stock Analysis page.
